JP2007500243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500243A5 JP2007500243A5 JP2006533559A JP2006533559A JP2007500243A5 JP 2007500243 A5 JP2007500243 A5 JP 2007500243A5 JP 2006533559 A JP2006533559 A JP 2006533559A JP 2006533559 A JP2006533559 A JP 2006533559A JP 2007500243 A5 JP2007500243 A5 JP 2007500243A5
- Authority
- JP
- Japan
- Prior art keywords
- growth hormone
- subject
- pharmaceutical composition
- plasma
- portal vein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000018997 Growth Hormone Human genes 0.000 claims 88
- 108010051696 Growth Hormone Proteins 0.000 claims 88
- 239000000122 growth hormone Substances 0.000 claims 88
- 239000008194 pharmaceutical composition Substances 0.000 claims 70
- 150000001875 compounds Chemical class 0.000 claims 42
- 210000003240 portal vein Anatomy 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 27
- 230000002440 hepatic effect Effects 0.000 claims 26
- 239000003623 enhancer Substances 0.000 claims 19
- 210000003169 central nervous system Anatomy 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- 239000007921 spray Substances 0.000 claims 9
- 239000003112 inhibitor Substances 0.000 claims 8
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 7
- 230000002411 adverse Effects 0.000 claims 7
- 238000010254 subcutaneous injection Methods 0.000 claims 7
- 239000007929 subcutaneous injection Substances 0.000 claims 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000012530 fluid Substances 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- 239000012528 membrane Substances 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 230000000593 degrading effect Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- 239000003961 penetration enhancing agent Substances 0.000 claims 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 3
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims 2
- 108010000521 Human Growth Hormone Proteins 0.000 claims 2
- 239000000854 Human Growth Hormone Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 102000014748 Junctional Adhesion Molecules Human genes 0.000 claims 2
- 108010064064 Junctional Adhesion Molecules Proteins 0.000 claims 2
- 239000002211 L-ascorbic acid Substances 0.000 claims 2
- 235000000069 L-ascorbic acid Nutrition 0.000 claims 2
- 208000002720 Malnutrition Diseases 0.000 claims 2
- 201000009623 Myopathy Diseases 0.000 claims 2
- -1 N-acetylamino acids Chemical class 0.000 claims 2
- 208000020221 Short stature Diseases 0.000 claims 2
- 102000013275 Somatomedins Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 230000000996 additive effect Effects 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
- 239000003833 bile salt Substances 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 210000004081 cilia Anatomy 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 239000012459 cleaning agent Substances 0.000 claims 2
- 239000003246 corticosteroid Chemical class 0.000 claims 2
- 229940097362 cyclodextrins Drugs 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 229940124447 delivery agent Drugs 0.000 claims 2
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 claims 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims 2
- 150000002081 enamines Chemical class 0.000 claims 2
- 208000028208 end stage renal disease Diseases 0.000 claims 2
- 201000000523 end stage renal failure Diseases 0.000 claims 2
- 229940125532 enzyme inhibitor Drugs 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 230000004136 fatty acid synthesis Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- 150000002314 glycerols Chemical class 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001071 malnutrition Effects 0.000 claims 2
- 235000000824 malnutrition Nutrition 0.000 claims 2
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000693 micelle Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 210000003097 mucus Anatomy 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000002840 nitric oxide donor Substances 0.000 claims 2
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 235000013772 propylene glycol Nutrition 0.000 claims 2
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 claims 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 235000011083 sodium citrates Nutrition 0.000 claims 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 2
- 229940001584 sodium metabisulfite Drugs 0.000 claims 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 229940124549 vasodilator Drugs 0.000 claims 2
- 239000003071 vasodilator agent Substances 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 230000003442 weekly effect Effects 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 102000002029 Claudin Human genes 0.000 claims 1
- 108050009302 Claudin Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010052437 Nasal discomfort Diseases 0.000 claims 1
- 102000003940 Occludin Human genes 0.000 claims 1
- 108090000304 Occludin Proteins 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012377 drug delivery Methods 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000541 pulsatile effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47740303P | 2003-06-09 | 2003-06-09 | |
| PCT/US2004/017632 WO2005004895A2 (en) | 2003-06-09 | 2004-06-01 | Compositions and methods for enhanced mucosal delivery of growth hormone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007500243A JP2007500243A (ja) | 2007-01-11 |
| JP2007500243A5 true JP2007500243A5 (https=) | 2007-07-26 |
Family
ID=34061913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533559A Withdrawn JP2007500243A (ja) | 2003-06-09 | 2004-06-01 | 成長ホルモンの増進された経粘膜送達のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050031549A1 (https=) |
| EP (1) | EP1643970A2 (https=) |
| JP (1) | JP2007500243A (https=) |
| CA (1) | CA2528465A1 (https=) |
| MX (1) | MXPA05013340A (https=) |
| WO (1) | WO2005004895A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
| US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| US7404489B1 (en) | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
| US20050129679A1 (en) | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
| US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
| WO2006110887A2 (en) * | 2005-04-11 | 2006-10-19 | Amylin Pharmaceuticals, Inc | Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling |
| EP1899462B1 (en) * | 2005-07-02 | 2011-03-09 | Arecor Limited | Stable aqueous systems comprising proteins |
| CU23317A1 (es) * | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
| JP2009504767A (ja) | 2005-08-17 | 2009-02-05 | フレミング・アンド・カンパニー・ファーマシューティカルズ | ビタミンｂ１２鼻用スプレーおよび使用方法 |
| GB0604319D0 (en) * | 2006-03-03 | 2006-04-12 | Optinose As | Nasal delivery |
| US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US7425542B2 (en) * | 2006-06-23 | 2008-09-16 | Aegis Therapeutics, Inc. | Stabilizing alkylglycoside compositions and methods thereof |
| US8084022B2 (en) * | 2006-06-23 | 2011-12-27 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008006019A2 (en) * | 2006-07-06 | 2008-01-10 | Advisys Inc. | Growth hormone releasing hormone treatment to decrease cholesterol levels |
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| EP2178547A4 (en) * | 2007-07-11 | 2011-02-16 | Aerovance Inc | PHARMACEUTICAL POLYPEPTIDE DRY POWDER AEROSOL FORMULATION AND MANUFACTURING METHOD |
| WO2009133408A2 (en) * | 2008-05-01 | 2009-11-05 | Arecor Limited | Protein formulation |
| EP2341940A1 (en) * | 2008-07-16 | 2011-07-13 | Arecor Limited | The stabilisation of proteins |
| EP2328607A1 (en) * | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
| JP6002385B2 (ja) * | 2008-09-12 | 2016-10-05 | クリティカル ファーマシューティカルズ リミテッドＣｒｉｔｉｃａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ | 医薬組成物、医薬組成物における吸収促進剤の使用方法、及び医薬組成物の製造方法 |
| WO2010080406A1 (en) * | 2008-12-18 | 2010-07-15 | Adrem Biotech, Inc. | Method for treating rhinitis and sinusitis by rhamnolipids |
| US8592381B2 (en) | 2008-12-18 | 2013-11-26 | Rhamnopharma Inc. | Method for treating rhinitis and sinusitis by rhamnolipids |
| WO2011065600A1 (en) * | 2009-11-25 | 2011-06-03 | Gcbio Corp. | Use of inhalable powder formulation comprising growth hormone for preventing or treating nmda receptor hypofunction-related diseases |
| EP2356998A1 (en) * | 2010-02-17 | 2011-08-17 | Université de Liège | A pharmaceutical composition for treatment of thrombosis-related diseases comprising a fragment of prolactin (PRL)-growth hormone (GH) - placental lactogen (PL)-family protein |
| UA111162C2 (uk) | 2010-08-04 | 2016-04-11 | Флекшен Терап'Ютікс, Інк. | Ін'єкційна композиція ацетоніду триамцинолону для лікування болю |
| KR20170058446A (ko) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| MX2013013098A (es) * | 2011-05-10 | 2013-12-16 | Nestec Sa | Metodos y composiciones para fomentar el crecimiento de la masa corporal magra. |
| JP2014513688A (ja) * | 2011-05-10 | 2014-06-05 | ネステク ソシエテ アノニム | 減量中に除脂肪量を保持するための方法及び組成物 |
| EP2739287B1 (en) * | 2011-08-04 | 2017-07-05 | Flexion Therapeutics, Inc. | Corticosteroids for the treatment of joint pain |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| JP5797227B2 (ja) * | 2013-05-21 | 2015-10-21 | パル ファーマシューティカル， インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP6097787B2 (ja) * | 2015-06-09 | 2017-03-15 | パル ファーマシューティカル， インコーポレーテッド | 鼻内送達用シアノコバラミン低粘度水性製剤 |
| WO2018020386A1 (en) * | 2016-07-27 | 2018-02-01 | Sun Pharmaceutical Industries Limited | Topical spray system of halobetasol |
| CA3070711C (en) | 2017-07-27 | 2023-09-19 | Locus Ip Company, Llc | Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances |
| WO2019133313A1 (en) | 2017-12-28 | 2019-07-04 | Locus Ip Company, Llc | Oral health composition comprising purified biosurfactants and/or their derivatives |
| WO2020019033A1 (en) * | 2018-07-25 | 2020-01-30 | Palmer Raymond Denis | Container for amylase inhibitor delivery |
| CR20210618A (es) | 2019-05-10 | 2022-03-11 | Locus Ip Co Llc | Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopelículas |
| US11918570B2 (en) | 2020-04-13 | 2024-03-05 | The Research Foundation For The State University Of New York | Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition |
| WO2023150267A1 (en) * | 2022-02-03 | 2023-08-10 | Maison Amori Oqvpo Llc | Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor |
| US20240299501A1 (en) * | 2023-03-06 | 2024-09-12 | Xygenyx Inc. | Composition and methods of treatment using transdermal hormone supplementation |
| CN121648113A (zh) * | 2026-02-06 | 2026-03-13 | 华中科技大学同济医学院附属同济医院 | 维生素b7在制备治疗变应性鼻炎的药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8712176D0 (en) * | 1987-05-22 | 1987-06-24 | Cosmas Damian Ltd | Drug delivery system |
| US5122804A (en) * | 1987-11-30 | 1992-06-16 | Radar Data Systems, Inc. | Method and apparatus for ground radar information display system |
| DK49791D0 (da) * | 1991-03-20 | 1991-03-20 | Novo Nordisk As | Nasalt pulverpraeparat |
| US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| US20020132803A1 (en) * | 2001-01-05 | 2002-09-19 | Mahendra Dedhiya | Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus |
-
2004
- 2004-06-01 JP JP2006533559A patent/JP2007500243A/ja not_active Withdrawn
- 2004-06-01 WO PCT/US2004/017632 patent/WO2005004895A2/en not_active Ceased
- 2004-06-01 US US10/862,141 patent/US20050031549A1/en not_active Abandoned
- 2004-06-01 CA CA002528465A patent/CA2528465A1/en not_active Abandoned
- 2004-06-01 MX MXPA05013340A patent/MXPA05013340A/es not_active Application Discontinuation
- 2004-06-01 EP EP04754279A patent/EP1643970A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007500243A5 (https=) | ||
| JP6422855B2 (ja) | インスリンおよびインスリン類似体の薬物動態及び薬力学、ならびに注射部位の疼痛を調節するためのマグネシウム組成物 | |
| Davis et al. | Absorption enhancers for nasal drug delivery | |
| JP7094242B2 (ja) | 低血糖症の治療用経鼻粉末製剤 | |
| ES2285860T3 (es) | Sistema de aporte de farmacos proteinicos usando mimeticos de membrana. | |
| US12257292B2 (en) | Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress | |
| JP2005537244A5 (https=) | ||
| WO1997006813A1 (en) | Mucosal preparation containing physiologically active peptide | |
| Nagai et al. | Bioadhesive dosage forms for nasal administration | |
| JP2008504249A (ja) | 糖尿病を治療するための方法 | |
| WO1995011042A1 (en) | Pernasal composition and pernasal preparation containing the same | |
| TW201717914A (zh) | 用於奈米顆粒冷凍乾燥形式的組成物及方法 | |
| Schipper et al. | Methylated β-cyclodextrins are able to improve the nasal absorption of salmon calcitonin | |
| WO2011141685A2 (fr) | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants | |
| JPH0228121A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
| CN102264346A (zh) | 用于通过颊透粘膜途径来施用降血脂药的制剂 | |
| US12324811B2 (en) | Intranasal formulation | |
| WO2021225973A1 (en) | Naloxone pharmaceutical formulations for intranasal (in) delivery | |
| US20250288548A1 (en) | Intranasal baclofen | |
| JP5845183B2 (ja) | トリプタン化合物を含む製剤 | |
| CA2713163C (fr) | Forme galenique pour l'administration de triptans par voie trans-muqueuse buccale | |
| CA1335076C (en) | Pharmaceutical composition and method for intranasal administration | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| CN110494135A (zh) | 包含扎那米韦的稳定的药剂学组合物 | |
| BR112020024399A2 (pt) | composição líquida sem água e sistema para administração transmucosal oral de um ingrediente ativo através de uma composição líquida |